8 unknown, 7 recruiting, 5 completed, 4 terminated. 9 Phase 3, 6 Not applicable, 5 Phase 2, 1 Phase 1, 1 Phase 4.
Follow Adjuvant Chemotherapy: new trials by email Literature Review of Adjuvant Chemotherapy trials Research Report on Adjuvant Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer Oxaliplatin plus S-1, Docetaxel plus S-1 - Gastric Cancer (GC), Adjuvant Chemotherapy | Phase 3 | Recruiting | Ruijin Hospital | 387 | 2025-12-15 | 2026-01-26 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Neoadjuvant cadonilimab combined with perioperative SOX, Neoadjuvant placebo plus perioperative SOX - Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy | Phase 3 | Recruiting | Zuoyi Jiao | 668 | 2025-05-15 | 2025-07-10 |
| Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Neoadjuvant apatinib combined with sintilimab and perioperative SOX, Neoadjuvant sintilimab combined with perioperative SOX - Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy | Phase 3 | Recruiting | Zuoyi Jiao | 682 | 2025-04-15 | 2025-04-22 |
| Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer Capecitabine - ctDNA, Colorectal Cancer (CRC) | Phase 2 | Recruiting | Fudan University | 80 | 2024-11-01 | 2026-05-01 |
| Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients Adjuvant Chemotherapy | Recruiting | HK inno.N Corporation | 36 | 2023-09-25 | 2024-04-29 | |
| Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo Codonopsis, Placebo - Pancreatic Carcinoma, Adjuvant Chemotherapy | Not applicable | Unknown | Zhejiang Provincial People's Hospital | 100 | 2022-10-25 | 2022-11-14 |
| Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer paclitaxel combined with platinum - Uterine Cervical Neoplasms, Chemoradiotherapy | Phase 3 | Recruiting | Fourth Affiliated Hospital of Guangxi Medical University | 108 | 2022-07-01 | 2023-02-21 |
| New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy Carboplatin, Paclitaxel, Nivolumab - Non-Small Cell Lung Cancer, Adjuvant Chemotherapy | Phase 3 | Active not recruiting | Fundación GECP | 210 | 2021-01-13 | 2026-05-05 |
| Adjuvant Chemotherapy in High Risk Stage II Colon Cancer FOLFOX/XELOX/Capecitabine - Stage II Colon Cancer, Adjuvant Chemotherapy | Phase 3 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 962 | 2020-08-01 | 2020-04-08 |
| Apatinib for Resectable Colorectal Cancer Apatinib, CAPEOX - Apatinib, Outcome, Fatal | Not applicable | Withdrawn | Nanchong Central Hospital | 2020-03-01 | 2024-11-14 | |
| A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan S-1 - Resected Pancreatic Cancer, Pancreatic Cancer | Phase 2 | Terminated | TTY Biopharm | 36 | 2019-07-11 | 2021-12-06 |
| Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis wait and watch, adjuvant chemotherapy - Colorectal Cancer, Adjuvant Chemotherapy | Not applicable | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 650 | 2019-04-30 | 2026-06-09 |
| Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer Breast Cancer, Adjuvant Chemotherapy | Terminated | Sun Yat-sen University | 226 | 2018-10-10 | 2021-01-29 | |
| IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy, Intensified Follow-up Schedule - Colorectal Cancer, Circulating Tumor DNA | Phase 2 | Unknown | Karen-Lise Garm Spindler | 64 | 2018-10-01 | 2022-02-25 |
| A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement) chemoradiation, Paclitaxel, Cisplatin - Cervical Cancer, Adjuvant Chemotherapy | Phase 3 | Unknown | Sun Yat-sen University | 432 | 2018-03-01 | 2018-03-26 |
| SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda - Colorectal Cancer Stage III, Adjuvant Chemotherapy | Phase 3 | Unknown | Peking University Cancer Hospital & Institute | 1191 | 2018-01-01 | 2020-03-06 |
| Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer PEG-rhG-CSF - Adjuvant Chemotherapy, Ovarian Neoplasms | Phase 4 | Terminated | Shandong University | 68 | 2017-12-01 | 2024-01-05 |
| Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) CapeOX（Capecitabine+Oxaliplatin）, Observation - Adjuvant Chemotherapy | Phase 3 | Unknown | Peking University Cancer Hospital & Institute | 1254 | 2017-06-01 | 2020-03-06 |
| Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Gemcitabine plus cisplatin, Capecitabine - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Completed | Asan Medical Center | 101 | 2017-05-15 | 2022-12-06 |
Showing 20 of 27. Sign in to see all of them.
Colorectal Neoplasms (6) · Colonic Neoplasms (4) · Stomach Neoplasms (3) · Breast Neoplasms (2) · Pancreatic Neoplasms (2) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Lung Diseases (1) · Lymphatic Metastasis (1) · Neoplasm Metastasis (1) · Neoplasm, Residual (1)
Neoplasms by Site (24) · Neoplasms (23) · Digestive System Diseases (18) · Digestive System Neoplasms (18) · Gastrointestinal Diseases (14) · Gastrointestinal Neoplasms (14) · Intestinal Diseases (11) · Intestinal Neoplasms (11) · Colonic Diseases (10) · Rectal Diseases (7) · Colorectal Neoplasms (5) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3)
Chemotherapy, Adjuvant (5) · Oxaliplatin (4) · Capecitabine (3) · Cisplatin (2) · Gemcitabine (2) · S 1 (combination) (2) · Carboplatin (1) · Chemoradiotherapy (1) · Docetaxel (1) · Doxorubicin (1) · Fluorouracil (1) · Folfox protocol (1) · HMPL-013 (1) · Nivolumab (1) · Observation (1)
Peking University Cancer Hospital & Institute (2) · Sun Yat-sen University (2) · Zuoyi Jiao (2) · Asan Medical Center (1) · Chinese Academy of Medical Sciences (1) · Fourth Affiliated Hospital of Guangxi Medical University (1) · Fudan University (1) · Fundación GECP (1) · HK inno.N Corporation (1) · Hellenic Cooperative Oncology Group (1) · Karen-Lise Garm Spindler (1) · Krankenhaus Barmherzige Schwestern Linz (1) · M.D. Anderson Cancer Center (1) · Nanchong Central Hospital (1) · Ruijin Hospital (1)
China (15) · Brazil (2) · South Korea (2) · Austria (1) · Denmark (1) · Greece (1) · Spain (1) · Taiwan (1) · United States (1)
Aiwen Wu, M.D. (2) · Arvind Dasari, MD (1) · Baek-Yeol Ryoo, MD (1) · Camila Bitu M. Braga, Msc (1) · Judith Lafleur, OA Dr. (1) · Jun Huang, MD/PHD (1) · Mariano Provencio, MD (1) · Myung-Ah Lee (1) · Selma Freire C. Cunha, PhD (1) · Wei-jun Ye, M.D (1) · Yunhong Tian (1) · Zhi-Hai Peng, MD (1) · Zhong-yu Yuan, M.D. (1)